Latest Renal cell carcinoma Stories
In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), has shown to dramatically improve progression-free survival for patients with advanced pancreatic neuroendocrine tumors (pNET), according to researchers from The University of Texas MD Anderson Cancer Center.
A breakdown of previous studies shows that compared with chemotherapy alone, use of the cancer drug bevacizumab in combination with chemotherapy or biological therapy is associated with an increased risk of treatment-related death.
An analysis of previous studies indicates that compared with chemotherapy alone, use of the cancer drug bevacizumab in combination with chemotherapy or biological therapy is associated with an increased risk of treatment-related death.
DURHAM, N.C., Jan.
Researchers at Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have developed a novel virus-based gene therapy for renal cell carcinoma that has been shown to kill cancer cells not only at the primary tumor site but also in distant tumors not directly infected by the virus.
EAST HANOVER, N.J., Dec.
NEW YORK, Dec. 2, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc.
BURLINGTON, Mass., Nov.
NEW YORK, Nov. 19, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc.
Galil Medical's TRACE Renal Registry tracks the use and effectiveness of kidney cryotherapy. Arden Hills, MN (PRWEB) November 18, 2010 Galil Medical, a global leader in minimally invasive cryotherapy cancer treatments, announced today that Medical University of South Carolina enrolled their first TRACE Registry patient.